On October 8, 2025, Theriva Biologics, Inc. presented promising preclinical data for their new cancer treatment, VCN-12, at a European Congress, indicating enhanced tumor destruction compared to their previous candidate VCN-01. The study showed significant tumor growth reduction in animal models and a strong immune response, suggesting potential for effective cancer therapy.